HONG KONG -- After four decades under a one-child policy, Chinese couples are now spending billions a year on fertility treatments, including a hefty amount overseas as they seek more reliable, accessible care.
Hong Kong-listed Mason Group Holdings is among those keen to tap this growing offshore demand. The financial and health services company has gone on an investment and acquisition spree in Hong Kong, Australia and Thailand to consolidate what it says is a promising but "fragmented" Asian market.
